In conclusion, modern TSS has a high final remission rate in treatment-naive microprolactinoma patients and may be an alternative first-line treatment option in addition to DA, particularly in those with preoperative PRL level of <200 ng/mL. The gene discussed is PRL; the disease is Microprolactinoma.